Partnology’s Post

I'm thrilled to share my latest article on the evolving landscape of CLL treatment and the market dynamics of BTK inhibitors, which is shared Microsoft news I delve into the projected dominance of Eli Lilly's Jaypirca in the BTK inhibitor market by 2032, highlighting its potential market share and the broader implications for the pharmaceutical industry. My analysis also covers the challenges and transitions faced by current market leaders like Imbruvica, and the rising significance of second-generation BTK inhibitors. #Oncology #Pharmaceuticals #BTKInhibitors #HealthcareAnalysis #EliLilly #Jaypirca #MarketInsights  GlobalData Plc GlobalData Healthcare #smallmolecules #majormarkets #research #dataanalysis #dataisfun #FDA #approval #btk #inhibitors #CLL #pharmaindustry #translationalmedicine #translationalresearch #drugdiscovery #drugdevelopment #oncology #clinicaltrials #elililly #globaldata #cancer #astrazeneca #abbvie #jhonsonandjhonson

Uncovering the potential of #ADCs to target tumours 👇 European Pharmaceutical Review discusses how #ADCs are set to play a pivotal role in the future of oncology, thanks to their potential to offer targeted treatments with a lower risk of side effects. Click the link below to read the article 🔗 https://lnkd.in/eNPmy5kg

Roche Terminates Collaboration with Repare Therapeutics for ATR Inhibitor Camonsertib Development Roche and Repare Therapeutics have ended their collaboration agreement for the development of camonsertib, a cancer therapy. Repare will now take over the development of camonsertib and is optimistic about its potential. The collaboration between Roche and Repare involved a significant upfront payment and had the potential to reach up to $1.2 billion based on various milestones. Recent milestones include Repare achieving a $40 million payment upon the initiation of a Phase II trial. Roche has terminated the agreement for camonsertib's development and commercialization, citing a review of its pipeline and external factors. Repare remains committed to the development of camonsertib and expects to meet its obligations under the agreement. For more details please click the link! https://lnkd.in/d_MqC7f9 #marketaccess #reimbursement #pricing #hta #heor #healtheconomics #medicaldevices #pharmaceutical

BioNTech SE's foray into #antibodydrugconjugates (ADCs) has hit a roadblock, with the FDA issuing a partial clinical hold on an early-stage study of one of the company's experimental #cancer drugs. https://lnkd.in/dRJBPkYZ #ADCs #biotechnology #clinicalresearch #clinicaltrials #drugdevelopment #FDA #oncology #pharmaceuticals #regulatoryaffairs

Clarity receives FDA Fast Track Designation for its diagnostic 64Cu-SAR-bisPSMA product. This designation, which is designed to expedite the development and regulatory review of novel drugs addressing serious conditions with significant unmet medical needs, provides a number of benefits in the development of 64Cu-SAR-bisPSMA, potentially reducing the New Drug Application (NDA) review time, allowing more frequent meetings with the FDA during development, and allowing Rolling Review of the planned NDA.   The Fast Track Designation is supported by the initial clinical evidence suggesting that 64Cu-SAR-bisPSMA may offer improved lesion detection compared to existing prostate cancer diagnostics. It comes at a time when Clarity is actively recruiting into its first registrational Phase III trial, CLARIFY, and preparing for an End of Phase meeting with the FDA for a second pivotal Phase III trial with 64Cu-SAR-bisPSMA.   Clarity is committed to advancing the development of this product to address the critical need for more accurate and accessible diagnostic tools in prostate cancer management. #biotech #radiopharmaceuticals #PSMA

🔬 Exploring the PD-1 and PD-L1 Inhibitors Market: Key players in the PD-1 and PD-L1 inhibitors market are leading the charge in immunotherapy, transforming cancer treatment. Merck (#Merck): Known for its groundbreaking Keytruda, Merck continues to set the standard in PD-1 inhibitors. Bristol-Myers Squibb (#BristolMyersSquibb): Innovating with Opdivo, BMS is at the forefront of immuno-oncology. Roche (#Roche): Pioneering with Tecentriq, Roche is pushing the boundaries of cancer care. AstraZeneca (#AstraZeneca): With Imfinzi, AstraZeneca is advancing therapies that improve patient outcomes. Ono Pharmaceutical (#OnoPharmaceutical): Collaborating with BMS, Ono Pharmaceutical is a vital player in PD-1 inhibitor development. Regeneron (#Regeneron): With Libtayo, Regeneron is making significant strides in cancer immunotherapy. Innovent (#Innovent): Innovent is leading in the Chinese market with its PD-1 inhibitor, Tyvyt. Hengrui Medicine (#HengruiMedicine): A major player in China, Hengrui is driving innovation in PD-1/PD-L1 treatments. Junshi Biosciences (#JunshiBiosciences): Junshi’s PD-1 inhibitor, Toripalimab, is making waves in global oncology. Merck KGaA (#MerckKGaA): Merck KGaA is committed to expanding the potential of PD-L1 inhibitors. #HealthcareInnovation #Oncology #CancerTreatment #Immunotherapy #Pharma #Biotech #MedicalResearch #LifeSciences #HealthcareTechnology #DrugDevelopment #PD1 #PDL1 #ImmunoOncology #CancerResearch #Pharmaceuticals #Biopharma #ClinicalTrials #CancerTherapy #MarketResearch #Biotechnology Read Report @ https://lnkd.in/giRPBpn9

Tablet dissolution modeling is on duty.

Latest Healthcare News & Updates: Adaptimmune’s Tecelra Becomes First FDA-Approved Engineered Cell Therapy for Solid Tumors. GSK Bags Sought-after JEMPERLI Okay in Endometrial Cancer.  MBX Biosciences, Inc. Rraises $63.5 Million in Series C Financing to Advance its Precision Endocrine Peptide™ (PEP™) Platform  FDA Hhalts Actinium Pharmaceuticals, Inc.'s Rradiotherapy Blood Cancer Plans, Prompting a Shift to Partnering  Otsuka Pharmaceutical Co., Ltd. Pays Up to $1.1B to Buy Jnana Therapeutics, Adds Drug Discovery Capabilities Get more detailed analysis, at: https://lnkd.in/gfzrB_Rn #lifesciences #pharmaceuticals #marketresearch #marketanalysis #healthcare #markettrends #health #medical #news #healthcarenews #pharmanews #clinicaltrials #clinicalresearch

Next-Generation ADCs Strive to Overcome Toxicities, Payload Problems Pharmaceutical companies are clamoring to add antibody-drug conjugates to their portfolios as the number of clinical trials explodes and the next generation rises. Antibody-drug conjugates (ADCs) are biotherapeutics comprised of a monoclonal antibody designed to recognize an antigen on a target cell, a potent cytotoxic payload that triggers cell death and a linker binding the antibody and payload together. They are developed and used to treat various cancer indications. “ADCs are a better chemotherapy,” said Joe Catanzaro, senior biotech analyst at Piper Sandler & Co. “There will always be efforts to move away from chemotherapy, and if you can replace chemotherapy, that obviously opens up a multitude of opportunities.” Chemotherapy is notorious for causing deleterious side effects due to its lack of specificity. ADCs are effectively targeted chemotherapy, delivering cancer-killing material directly to malignant cells. https://lnkd.in/g29JBZ7R

Coherus BioSciences has recently sold the rights to its adalimumab biosimilar Yusimry to HKF Pharmaceuticals for $40 million. Coherus BioSciences is making the strategic decision to focus its efforts on oncology, as evidenced by the following: - 𝘀𝗮𝗹𝗲 𝗼𝗳 𝘁𝗵𝗲 𝗿𝗶𝗴𝗵𝘁𝘀 𝘁𝗼 𝗶𝘁𝘀 𝗮𝗱𝗮𝗹𝗶𝗺𝘂𝗺𝗮𝗯 𝗯𝗶𝗼𝘀𝗶𝗺𝗶𝗹𝗮𝗿 𝗬𝘂𝘀𝗶𝗺𝗿𝘆 𝘁𝗼 𝗛𝗞𝗙 𝗣𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹𝘀 for $40 million, allowing the company to focus on its oncology pipeline - 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗼𝗳 𝗮𝗻 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗶𝗺𝗺𝘂𝗻𝗼-𝗼𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝗽𝗶𝗽𝗲𝗹𝗶𝗻𝗲 that includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to treat cancer which includes candidates such as CHS-006 (a TIGIT-targeted antibody), CHS-1000 (targeting the ILT4 pathway), and CHS-114 (a selective anti-CCR8 antibody) - 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗰𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝘁𝗵  𝗜𝗡𝗢𝗩𝗜𝗢 to evaluate its PD-1 inhibitor LOQTORZI in combination with INOVIO's INO-3112 in a Phase 3 trial for cancer treatment ------ I am Matteo Boemi and I support you in market knowledge and strategy. How? Since 2001, I have been involved in business, market, and competitive intelligence, helping companies define strategies in line with market and competitive scenarios. #marketintelligence #competitiveintelligence #strategy #marketsmind #pharmaceutical